Q4 23: destocking noise offsets recovery in other key segments
08/02/24 -"Novozymes reported a mixed set of Q4 23 numbers, missing at the top line but beating on the bottom line. While the innovation-driven momentum in BioEnergy was complemented by an encouraging recovery ..."
Pages
51
Language
English
Published on
08/02/24
You may also be interested by these reports :
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...
05/03/26
Who would have believed that amongst the star-studded European pharma names, the tiny (in market cap terms, relative to Big Pharmas) Faes Farma (ADD; ...
04/03/26
The Q4 results exceeded expectations, with Crop Science being a key top-line driver. Adjusted EBITDA declined for all three divisions. While the 2026 ...